BioNTech’s Oncology Pipeline Faces Its Biggest Test Yet as Bernstein and Consensus Diverge by 38%
23.05.2026 - 07:33:28 | boerse-global.de
The coming week could determine whether BioNTech’s stock finally starts to reflect its clinical progress or remains stuck in a valuation rut. As the American Society of Clinical Oncology kicks off in Chicago on 29 May, the German biotech is bringing a dense data package — but the market remains deeply divided on what it is worth.
Just days before the meeting, Bernstein initiated coverage with a “Market Perform” rating and a $96 price target, a level far below the average view among 17 analysts covering the stock. The broader sell-side consensus calls the shares a “Buy” and pegs the median price target at $125.45, implying upside of roughly 38% from current levels. That gap — $96 versus $125.45 — captures the tension between Bernstein’s valuation discipline and the market’s hopes for a pipeline breakthrough.
The divergence is not about the science, at least not entirely. Analyst Jeffrey Walch acknowledged BioNTech’s strong financial foundation — €16.8 billion in cash at the end of the first quarter — but flagged elevated regulatory and approval risks for the company’s oncology candidates. J.P. Morgan had recently reiterated a “Hold” rating, adding to the mixed signals. Meanwhile, the stock ended the week at €79.50, barely 10% above its 52-week low of €72.50 and roughly 22% below the year’s high. Over the past month alone the shares have lost more than 15%, and the relative strength index of 50.6 suggests no clear momentum in either direction.
Investors will now weigh Bernstein’s caution against the data BioNTech plans to present at ASCO. Two oral presentations anchor the company’s presence at the world’s largest oncology conference.
Should investors sell immediately? Or is it worth buying BioNTech?
The first centers on Pumitamig, a bispecific immunomodulator that combines PD-L1 checkpoint inhibition with VEGF-A neutralization, developed jointly with Bristol Myers Squibb. In the phase 2/3 ROSETTA Lung-02 trial, the drug showed encouraging anti-tumor activity in first-line non-small cell lung cancer when paired with chemotherapy. This marks the third data set to deliver consistent positive signals, following earlier results in small cell lung cancer and triple-negative breast cancer. The ongoing pivotal phase 3 portion of the ROSETTA study is now comparing Pumitamig plus chemotherapy directly against the standard-of-care combination of pembrolizumab and chemotherapy.
The second oral presentation covers Gotistobart, a CTLA-4 antibody designed to selectively deplete regulatory T cells. In the phase 2 PRESERVE-004 trial, heavily pre-treated patients with platinum-resistant ovarian cancer achieved clinically meaningful overall survival when treated with Gotistobart plus pembrolizumab — and without chemotherapy. The safety profile was described as manageable, raising the possibility of a chemotherapy-free option in a difficult-to-treat population.
Behind the ASCO data lies a company in transition. First-quarter revenue fell to $138 million as COVID-19 vaccine sales continued to shrink. The net loss widened to $622 million, while research and development spending climbed to $651.6 million, driven by investments in oncology and antibody-drug conjugates. Despite the burn, BioNTech maintains a cash cushion of $19.6 billion and has held its 2026 revenue forecast steady at $2.3 billion to $2.6 billion.
BioNTech at a turning point? This analysis reveals what investors need to know now.
Management has also authorized a share buyback program of up to $1 billion over twelve months — a signal that the board sees the current price as undervalued. But the company’s ambitious pipeline expansion continues: more than 25 phase 2 and phase 3 trials are under way, including 13 pivotal studies. Another six phase 3 trials are expected to launch before year-end, and seven late-stage data packages are due by the end of 2026. For Trastuzumab pamirtecan, BioNTech plans to file a marketing application in the US this year for HER2-expressing endometrial cancer.
ASCO’s oral presentations on Pumitamig and Gotistobart now serve as the most immediate test of whether the data can begin to close the gap between the current share price and the consensus target. With the stock trading 22% below its 2026 high and the analyst community split, the next few days could either validate Bernstein’s caution — or prove it overly conservative.
Ad
BioNTech Stock: New Analysis - 23 May
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
